Singular Genomics Systems Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Singular Genomics Systems Inc (OMIC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Singular Genomics Systems Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3M vs 86,690M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-39.1% annualized vs trailing 12 months), vs decelerating (-10.0%) for its tracked peer group.
- Growth: Singular Genomics Systems Inc generated -12.1% revenue growth year over year in Q3 2024, vs 1.8% for its competitors combined.
- Profitability: Its -4,136.7% net margin compares with 17.4% for the peer group.
- Peer revenue share: Singular Genomics Systems Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.40M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OMIC Sales vs. its Competitors, Q3 2024
Singular Genomics Systems Inc reported revenue contraction of 12.12 % year on year in Q3 2024, below its competitors' combined revenue growth of 1.83 %.
With a net margin of -4,136.70 %, Singular Genomics Systems Inc reported lower profitability than its competitors (17.42 %).
Singular Genomics Systems Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Singular Genomics Systems Inc vs. its Competitors, Q3 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Singular Genomics Systems Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Singular Genomics Systems Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Singular Genomics Systems Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Singular Genomics Systems Inc's competitor groups requires a Commercial License.
For context: the Laboratory Analytical Instruments industry grew revenue 13.0% year over year, combined, vs -12.1% for Singular Genomics Systems Inc. Singular Genomics Systems Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Singular Genomics Systems Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Singular Genomics Systems Inc | - | Yes | No | No |
| Competitors combined (20) | ||||
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OMIC Stock Performance relative to its Competitors
OMIC Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | 10x Genomics Inc | 282.9% | Outperformed |
| 2 | Illumina Inc | 282.9% | Outperformed |
| 3 | Nautilus Biotechnology Inc | 282.9% | Outperformed |
| 4 | Revvity Inc | 282.9% | Outperformed |
| 5 | Bruker Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Singular Genomics Systems Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Singular Genomics Systems Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Singular Genomics Systems Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Singular Genomics Systems Inc |
50.05 | 2.67 |
 Thermo Fisher Scientific Inc |
267,724.73 | 47,351.00 |
 Agilent Technologies inc |
50,988.11 | 7,372.00 |
 Beone Medicines Ltd |
47,669.97 | 6,606.28 |
 Mettler toledo International Inc |
35,538.66 | 4,133.88 |
 Illumina Inc |
34,000.12 | 4,538.00 |
| SUBTOTAL | 495,243.67 | 86,694.09 |
Sign in to see all competitors of Singular Genomics Systems Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Singular Genomics Systems Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Singular Genomics Systems Inc's Competitors Named by the Company
Competitive relationships identified from Singular Genomics Systems Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Element Biosciences, Inc. | Company report | 85% |
| Ultima Genomics, Inc. | Company report | 85% |
| Pacific Biosciences Inc. | Company report | 85% |
| Atlantic International Corp | Company report | 85% |
| SQL | Company report | 85% |
| Thermo Fisher Scientific Inc. | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Illumina Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Nautilus Biotechnology Inc | Company report | 85% |
| 10x Genomics Inc | Company report | 85% |
| Standard Biotools Inc | Company report | 85% |
| Bionano Genomics Inc | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| Avantor Inc | Company report | 85% |
| Seer Inc | Company report | 85% |
| Mettler toledo International Inc | Company report | 85% |
| Bruker Corporation | Company report | 85% |
| Revvity Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Singular Genomics Systems Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Singular Genomics Systems Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Thermo Fisher Scientific Inc | Clinical Research 20.15 % |
| Agilent Technologies inc | Agilent CrossLab 41.36 % |
| Mettler toledo International Inc | US Operations 35.68 % |
| Illumina Inc | Sequencing 90.43 % |
| Avantor Inc | VWR Distribution & Services 72.65 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Singular Genomics Systems Inc .
Singular Genomics Systems Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Singular Genomics Systems Inc | 50 | 14,032 | -454,326 |
| Thermo Fisher Scientific Inc | 267,725 | 378,808 | 56,712 |
| Agilent Technologies inc | 50,988 | 407,293 | 79,558 |
| Beone Medicines Ltd | 47,670 | 550,523 | 76,298 |
| Mettler toledo International Inc | 35,539 | 249,029 | 54,555 |
| Illumina Inc | 34,000 | 3,545,313 | 699,219 |
| PEERS TOTAL | 495,194 | 395,642 | 56,441 |
Sign in to see all peers for Singular Genomics Systems Inc .
Singular Genomics Systems Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Thermo Fisher Scientific Inc | North America 51.63 % |
| Agilent Technologies inc | Americas 41.63 % |
| Beone Medicines Ltd | United States 54.39 % |
| Mettler toledo International Inc | Us Operations segment 35.68 % |
| Illumina Inc | United States and Canada 56.42 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Singular Genomics Systems Inc .
Singular Genomics Systems Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Laboratory Analytical Instruments industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (49 companies). See the full Laboratory Analytical Instruments industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | -50.83 % | 34.50 % (avg) | -85.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -12.73 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 15.94 % | 3.87 % (avg) | +12.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Singular Genomics Systems Inc's Valuation vs Competitive Position
Valuation multiples vs the Laboratory Analytical Instruments industry average (49 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Laboratory Analytical Instruments industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 33.2x | - |
| EV / EBITDA | - | 20.6x | - |
| P/B | 0.1x | 2.9x | -2.8x |
| Return on Equity | -57.87 % | industry aggregate | -57.74 % |
| Return on Invested Capital | -25.85 % | -10.58 % (avg) | -15.27 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Singular Genomics Systems Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | -2.00 % | -15.06 % | -21.46 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Singular Genomics Systems Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 15.94 % vs industry average 3.87 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Singular Genomics Systems Inc's dedicated Suppliers and Customers pages, not here.
Singular Genomics Systems Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 57.7 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-39.1% annualized vs trailing 12 months).
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-10.0% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Singular Genomics Systems Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Singular Genomics Systems Inc | 1.79 | 9.25 | 0.05 |
| Thermo Fisher Scientific Inc | 0.39 | 1.69 | 0.81 |
| Agilent Technologies inc | 0.77 | 2.02 | 1.02 |
| Beone Medicines Ltd | 2.58 | 3.50 | 0.21 |
| Mettler toledo International Inc | 0.04 | 1.13 | - |
| Illumina Inc | - | 2.02 | 0.68 |
Sign in to see all peers for Singular Genomics Systems Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Singular Genomics Systems Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Singular Genomics Systems Inc | Q3 2024 | -12.1 % | - |
| Thermo Fisher Scientific Inc | Q3 2026 | +9.1 % | +6.2 % |
| Agilent Technologies inc | Q2 2026 | +8.1 % | +7.7 % |
| Beone Medicines Ltd | Q2 2026 | +33.9 % | +208.2 % |
| Mettler toledo International Inc | Q2 2026 | +4.5 % | +15.1 % |
| Illumina Inc | Q3 2026 | +4.2 % | +46.7 % |
| PEERS TOTAL | +8.8 % | +176.3 % |
Sign in to see all peers for Singular Genomics Systems Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Singular Genomics Systems Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Singular Genomics Systems Inc | Q3 2024 | +34.2 % | -93.6 % |
| Thermo Fisher Scientific Inc | Q3 2026 | +133.0 % | +8.2 % |
| Agilent Technologies inc | Q2 2026 | -1.6 % | -22.3 % |
| Beone Medicines Ltd | Q2 2026 | +10.7 % | -26.8 % |
| Mettler toledo International Inc | Q2 2026 | +30.3 % | +16.4 % |
| Illumina Inc | Q3 2026 | -14.8 % | +29.0 % |
Sign in to see all peers for Singular Genomics Systems Inc .
Singular Genomics Systems Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Singular Genomics Systems Inc | - | - | - |
| Thermo Fisher Scientific Inc | 6.29% | 7.46% | 13.32% |
| Agilent Technologies inc | 10.97% | 19.84% | 41.99% |
| Beone Medicines Ltd | 10.23% | 13.17% | 18.21% |
| Mettler toledo International Inc | 24.86% | 34.41% | - |
| Illumina Inc | 13.43% | 18.74% | 31.45% |
Sign in to see all peers for Singular Genomics Systems Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Singular Genomics Systems Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Singular Genomics Systems Inc | - | 18.77 |
| Thermo Fisher Scientific Inc | 38.14 | 5.65 |
| Agilent Technologies inc | 35.54 | 6.92 |
| Beone Medicines Ltd | 53.47 | 7.22 |
| Mettler toledo International Inc | 39.81 | 8.60 |
| Illumina Inc | 38.13 | 7.49 |
| PEERS AVERAGE | 40.33 | 5.71 |
Sign in to see all peers for Singular Genomics Systems Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.